Durect Corp. said Friday it was still “working through the logistics” of changes wanted by the FDA in the already-started phase III trial called Persist with Posimir, an extended-release form of bupivacaine delivered via depot for pain after surgery, and Wall Street nicked the shares only slightly as the focus remains on Remoxy (oxycodone), for which the new drug application (NDA) was resubmitted last month.